

ASX Announcement

2 June 2026

XENITRA APPOINTED EXCLUSIVE CHINA DISTRIBUTOR FOR BIOMIQ SKINCARE

2 June 2026. Hong Kong, China. Xenitra Limited (ASX: XEN) or (the “Company”) is pleased to announce that it has entered an exclusive distribution agreement with Servatus Ltd (“Servatus”) appointing the Company as the **exclusive distributor of Biomiq Skincare in Greater China** in a 4-year exclusive agreement targetting **minimum offtake of \$5 million**. (“Biomiq Agreement”).

Xenitra is pioneering a dynamic blockchain **tokenised sales ecosystem** in Asia, specialised in fast-moving consumer goods and **Biomiq Skincare is the second major brand to join** the tokenised sales ecosystem after the launch of EZZ earlier in April with strong initial sales.

Highlights

- The agreement defines **minimum offtake of products from Biomiq of \$5m** to retain exclusivity, being \$0.5m, \$1m, \$1.5m and \$2.0m in the first four years, respectively.
- The **Biomiq Skincare range includes more than 20 SKUs** with a specialisation in **Acne Treatment and Prevention, Minor skin conditions** (eczema, psoriasis, skin irritation) and a potent range of **Anti-aging formulas** designed for the menopause/perimenopause skincare market.
- **Biomiq Skincare is made in Australia** by Australian Biotherapeutics, a part of the Servatus Biopharmaceuticals Group of companies, based in Queensland.
- **Biomiq is one of Australia's fastest growing skincare brands** having seen rapid sales growth since 2025 through strong social media and online marketing strategies.
- The agreement commences with a **target launch date of August 2026** and spans **4 years**.
- Biomiq Skincare will be the **second brand to be integrated into the OPAL tokenised sales ecosystem** and will be exclusively distributed in Greater China by Xenitra.
- The OPAL ecosystem is designed as a **self-reinforcing commercial flywheel** that aimed at scaling capable of supporting multiple brands in the ecosystem.



ASX Announcement

2 June 2026

Non Executive Chairman, Dr Anthony Noble, commented: *"I am very proud to see the Biomiq skincare range join Xenitra's tokenised sales channel in China. This represents an exciting new line of products with significant commercial potential in the China market, treating the world's eighth most prevalent condition, acne vulgaris and now also expanding with potent anti-aging formulas that have even greater potential in China, in line with the needs of an aging population. They are a natural fit for the tokenised sales channel having shown growth in the Australian market, very high customer repurchase rates and viral uptake via social media led ecommerce marketing.*

"With sales in the first 6 weeks now approaching \$1m, the real-world asset (RWA) tokenisation ecosystem is an exciting and now proven sales model. It creates a compelling opportunity to deepen engagement, strengthen loyalty and allows broad participation by customers and consumers. For international brands looking to enter the Asian market, the ecosystem provides the capacity for product authentication and full traceability which addresses key commercial concerns, while also providing a strong incentive for consumers to purchase and trial new products from premium brands through the loyalty and rewards program. Importantly, this sales channel is supported by established business fundamentals, including high-repurchase rate products, proven user networks across multiple markets, and recurring sales momentum within the product range on sale in the channel."

About Biomiq Skincare and Servatus Biopharmaceuticals Group

Biomiq (www.biomiq.com.au) is a range of advanced Australian made skincare designed to rebalance the skin microbiome, reinforce the skin barrier, and reduce inflammation at its source. Biomiq skincare launched in 2022, based on a discovery made by Servatus Biopharmaceuticals in Queensland, Australia. Biomiq products are developed and made in Australia using their BioQx™ proprietary technology - designed to support the microbiome-barrier-inflammation axis of skin health. Biomiq's philosophy is that long-term skin clarity and resilience depends on restoring biological balance – not aggressively suppressing symptoms. Their formulas include the BioQx™ complex of functional microbial metabolites, barrier-supportive ceramides, active anti-inflammatory botanical extracts and biocompatible actives.

Servatus Ltd (www.servatus.com.au) was established in 2012, beginning operations in 2013, and is a vertically integrated biotechnology company. Servatus is the owner of Australian Biotherapeutics, a precision fermentation continuous bioreactor production facility located in Coolool Queensland and have two biotechnology drug development platforms: Engineered Proteins for the treatment of autoimmune diseases, and Live Biotherapeutics (LBPs) for the treatment of inflammatory conditions and bacterial infections. They are developing SVT-6A4710 for Rheumatoid Arthritis (RA) (Phase 2), SVT-4A1011 for Insomnia (Phase 2a), SVT1B149 for Irritable Bowel Syndrome - Constipation (IBS-C) (Phase 1/2a), SVT-1A4710 for Inflammatory Bowel Disease / Ulcerative Colitis (IBD-UC) (HREC/IND – Phase 1) and Recombinant Protein Therapeutic SVT-Bax (1-10) for Rheumatoid arthritis (RA) (Preclinical program (PK/PD)). The company discovered the novel BioQx™ complex which had potent applications for modulating the skin microbiome, reducing skin inflammation and restoring skin barrier function. The BioQx™ complex has formed the basis of the Biomiq skincare range of products which is now the commercial focus of the company's consumer health division.

ASX Announcement

2 June 2026

Key Terms of the Distribution Agreement

- **Distributor:** M Best Tax Free Pty Limited (wholly owned subsidiary of the Company)
- **Supplier:** Servatus Ltd
- **Territory:** Greater China
- **Term:** commences on 2 June 2026 and will continue for a 4-year term ("Initial Term"). Upon expiry of the Initial Term, the Biomiq Agreement automatically renews for consecutive 3-year renewal terms ("Renewal Term") unless either party provides 90 days' written notice prior to expiry.
- **Exclusivity:** XEN appointed exclusive distributor across all channels of Biomiq products under the Biomiq Agreement.
- **Payment Terms:** 50% of the invoice value is payable upon receipt of invoice, with the remaining 50% payable within 75 days of the invoice date.
- **Minimum purchase commitments:** XEN must purchase Biomiq products from Servatus of at least \$0.5 million in year one, \$1 million in year two, \$1.5 million in year three and \$2.0 million in year four. If these minimum purchase requirements are not met, Servatus may terminate the exclusive distribution rights for the products from the following contract year.
- **Termination:** If either party wishes to terminate the Biomiq Agreement upon expiration of the Initial Term or a Renewal Term, the terminating party must provide written notice to the other party 90 days prior to the expiration of the Initial Term or the Renewal Term (as applicable). Either party may also elect to terminate at the 2-year anniversary of the Initial Term with 180 days' notice.
Additionally, Either party may immediately terminate the Biomiq Agreement by giving written notice to the other party if:
 - the other party is in breach of any material provision of the Biomiq Agreement and, where the breach is capable of remedy, the party in breach has failed to remedy the breach within 30 days of receipt of written notice from the other party describing the breach and calling for it to be remedied; or
 - subject to the other party becomes insolvent.

Due Diligence and Related Party Disclosure

Anthony Noble is an Executive Director of Servatus Limited and is a Non-Executive Director of Xenitra Limited. He is not a shareholder in either company currently, he holds 40 million options priced at 0.4c in Xenitra Limited (vesting on achievement of \$75 million annual audited revenue and 2 consecutive cashflow positive quarters being reported) and holds 700,000 options priced at 15c in Servatus Limited. Dr Noble will receive no financial benefit from either company arising due to the contract, beyond his director fees from Xenitra and salary from Servatus both of which are unaffected by the contract or sales under the contract. He has not been involved in the approval of the distribution agreement by either company or the negotiation of the commercial terms of the agreement. Dr Noble was absent from and did not vote on the approval of the Biomiq Agreement.

Independent directors assessed and approved the transaction on arm's length terms, including Servatus' capacity to supply the volume of products contracted for.

ASX Announcement

2 June 2026

-Ends-

This announcement has been approved for release By The Board of Xenitra Limited.

Investor Relations Contact:

Blackwater Advisors

Harry Spillane | **Investor Relations**

harry@blackwateradvisors.com.au

+61 447 757 550

About Xenitra Limited

Xenitra specialises in fast-moving consumer goods (FMCG), nutraceuticals, over-the-counter (OTC) medicine and personal care products that are sold through a channel optimised sales ecosystem including blockchain tokenised distribution channels spanning Business-to-Business (B2B) trading, retail distribution and all major ecommerce platforms in China. Xenitra is an established brand acceleration partner for western brands entering the Asian markets. Through our proprietary platform, we have a proven track record of delivering exceptional market integration, providing marketing insights and delivering sales velocity.

Forward Looking Statements

This announcement may contain forward-looking statements, including statements regarding: plans, strategies and objectives of management; anticipated revenue, products, and stores; operating costs; Chinese tourism; Governmental policies and preferences (both Australian and Chinese). Forward-looking statements can be identified by the use of terminology such as 'intend', 'aim', 'project', 'anticipate', 'estimate', 'plan', 'believe', 'expect', 'may', 'should', 'will', 'continue', 'annualised' or similar words. These statements discuss future expectations concerning the results of operations or financial condition, or provide other forward-looking statements. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements. Except as required by applicable regulations or by law, the Group does not undertake any obligation to publicly update or review any forward-looking statements, whether as a result of new information or future events. Past performance cannot be relied on as a guide to future performance.